Pheochromocytoma and functional paraganglioma

Current Opinion in Oncology

Volumn 16, Issue 1, 2004, Pages 8-12

  Roman, Sanziana ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypertension; Paragangliomas; Pheochromocytomas

Indexed keywords

CATECHOLAMINE; CYCLOPHOSPHAMIDE; DACARBAZINE; NEUROPEPTIDE Y; PEPTIDE; RADIOPHARMACEUTICAL AGENT; VINCRISTINE;

ADRENAL TUMOR; CANCER PATIENT; CANCER RADIOTHERAPY; CATECHOLAMINE RELEASE; CHROMAFFIN CELL; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; FAMILIAL DISEASE; FUNCTIONAL PARAGANGLIOMA; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; HYPERTENSION; IMAGE ANALYSIS; INCIDENCE; MISSENSE MUTATION; MOLECULAR BIOLOGY; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; PARAGANGLIOMA; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; SURGICAL TECHNIQUE; SYMPTOM; TUMOR LOCALIZATION; VON HIPPEL LINDAU DISEASE; DIFFERENTIAL DIAGNOSIS;

ADRENAL GLAND NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERTENSION; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS;

EID: 2442446468     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200401000-00003     Document Type: Review

References (32)

1. Smythe GA, Edwards G, Graham P, et al.: Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine. Clin Chem 1992, 38:486-492.
2. Crout JR, Sjoredsma A: Turnover and metabolism of catecholamine in patients with pheochromocytoma. J Clin Invest 1964, 43:94-102.
3. Bravo EL, Tagle R: Pheochromocytoma: state of the art and future prospects. Endocr Rev 2003, 24:539-553. This is a comprehensive review of the current understanding of pathophysiology and clinical manifestations of pheochromocytoma, discussing alternative antihypertensive treatments and innovative anesthetic techniques.
4. Bravo EL: Pheochromocytoma: an approach to antihypertensive therapy. Ann N Y Acad Sci 2002, 970:1-10. This is an excellent overview of all the currently available medical therapy for pheochromocytomas.
5. Langer SZ, Cavero I, Massingham R: Developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension 1980, 2:372-382.
6. deS Senanayake P, Denker J, Bravo EL, et al.: Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest 1995, 96:2503-2509.
7. Sipple JH: The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961, 31:163-166.
8. Decker RA, Peacock ML: Occurrence of MEN2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene. J Pediatr Surg 1998, 33:207-214.
9. Koch CA, Vortmeyer AO, Zhuang Z, et al.: New insights into the genetics of familial chromaffin cell tumors. Ann N Y Acad Sci 2002, 970:11-28. This is a comprehensive review of genetic aspects of familial chromaffin cell tumors including a good discussion of pathophysiology and molecular basics.
10. Vortmeyer AO, Huang SC, Pack SD, et al.: Somatic point mutations of the wildtype allele detected in tumors of patients with VHL germline deletion. Oncogene 2002, 21:1167-1170.
11. Koch CA, Huang SC, Zhuang Z, et al.: Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma. Oncogene 2002, 21:479-482.
12. Hes FJ, Hoppener JW, Lips CJ: Pheochromocytoma in von Hippel Lindau disease. J Clin Endocrinol Metab 2003, 88:969-976.
13. Hoffman MA, Ohh M, Yang H, et al.: von Hippel-Lindau protein mutants linked to type 2 C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001, 10:1019-1027.
14. Fodde R, Smits R: Tumor suppressor genes: it's all about dosage. Science 2002, 298:761-763.
15. Neumann HP, Bausch B, McWhinney SR, et al.: Germline mutations in non-syndromic pheochromocytoma. N Engl J Med 2002, 346:1459-1466. This is a seminal paper on the molecular aspects of pheochromocytoma from the Freiburg-Warsaw-Columbus Pheochromocytoma Study Group.
16. Gutmann DH, Geist RT, Rose K, et al.: Loss of neurofibromatosis type 1 gene expression in pheochromocytomas from patients without NF1. Genes Chromosomes Cancer 1995, 13:104-109.
17. Zapata P, Hess S, Bliss AL, et al.: Chemical, electron microscopic and physiological observations on the role of catecholamines in the carotid body. Brain Res 1969, 14:473-496.
18. Baysal BE, Ferrell RE, Willett-Brozick JE, et al.: Mutations in SDHD, a mitochondrial complex II gene in hereditary paraganglioma. Science 2000, 287:848-851.
19. Edstrom Elder E, Hjelm Skog A, Hoog A, et al.: The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 2003, 29:278-283.
20. Astrom K, Cohen JE, Willett-Brozick JE, et al.: Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum Genet 2003, 113:228-237.
21. Meijer WG, Copray SC, Hollema H, et al.: Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clin Chem 2003, 49:586-593.
22. Sawka AM, Roman J, Ravinder JS, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003, 88:553-558.
23. Lenders JW, Pacak K, Walther MM, et al.: Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002, 287:1427-1434.
24. Eisenhofer G, Goldstein DS, Walther MM, et al.: Biochemical diagnosis of pheochromocytoma: how to distinguish true from false positive test results. J Clin Endocrinol Metab 2003, 88:2656-2666.
25. Lenders JW, Pacak K, Eisenhofer G: New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. Ann N Y Acad Sci 2002, 970:29-40. This paper reviews the historical developments in the diagnosis of pheochromocytoma in relation to recent data on new diagnostic serum laboratory modalities.
26. Rao F, Keiser HR, Oconnor DT: Malignant and benign pheochromocytoma: chromaffin granule transmitters and the response to medical and surgical treatment. Ann N Y Acad Sci 2002, 971:530-532.
27. Yon L, Guillemot J, Montero-Hadjadje M, et al.: Identification of the secretogranin II derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J Clin Endocrinol Metab 2003, 88:2679-2685.
28. Roman SA, Kinder BKK: Pheochromocytoma. In Cameron's Current Surgical Therapy, 8th ed. Cameron J, editor, Mosby Inc, St. Louis, MO.
29. LeRest B, Bomanji JB, Costa DC, et al.: Functional imaging of malignant paragangliomas and carcinoid tumors. Eur J Nucl Med 2001, 28:478-482.
30. Ikeda Y, Takami H, Tajima G, et al.: Laparoscopic partial adrenalectomy Biomed Pharmacother 2002, 56(suppl 1):126s-131s.
31. Matsuda T, Murota T, Oguchi N, et al.: Laparoscopic adrenalectomy for pheochromocytoma: a literature review. Biomed Pharmacother 2002, 56(suppl 1):132s-138s.
32. Sisson JC: Radiopharmaceutical treatment of pheochromocytomas. Ann N Y Acad Sci 2002, 970:54-60.